menu
    • menu
    [{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Beijing Continent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"Hydronidone","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gyre Therapeutics \/ Beijing Continent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gyre Therapeutics \/ Beijing Continent Pharmaceuticals"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"F230","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gyre Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Gyre Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Nanjing Healthnice Pharmaceutical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Gyre Therapeutics \/ Nanjing Healthnice Pharmaceutical Technology","highestDevelopmentStatusID":"14","companyTruncated":"Gyre Therapeutics \/ Nanjing Healthnice Pharmaceutical Technology"}]

    Find Clinical Drug Pipeline Developments & Deals by Gyre Therapeutics

    Menu

    Gyre Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gyre Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Gyre Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avatrombopag Maleate

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Nanjing Healthnice Pharmaceutical Technology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gyre Therapeutics Gets NMPA Approval for Avatrombopag in CLD-Associated Thrombocytopenia

                            Details : Avatrombopag Maleate, a thrombopoietin receptor agonist is approved by NMPA china. It is given orally for the treatment of thrombocytopenia associated with chronic liver disease.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 02, 2024

                            Lead Product(s) : Avatrombopag Maleate

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Nanjing Healthnice Pharmaceutical Technology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gyre Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Gyre Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : F230

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gyre Pharmaceuticals Gets IND Approval from NMPA for F230 in Pulmonary Hypertension

                            Details : F230 is an oral, a selective endothelin receptor antagonist, which is being evaluated for the treatment of patients with pulmonary arterial hypertension.

                            Brand Name : F230

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2024

                            Lead Product(s) : F230

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gyre Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Gyre Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydronidone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Beijing Continent Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Catalyst Biosciences Announces Completion of Business Combination with Beijing Continent Pharmaceuticals and I...

                            Details : The combined company will more efficiently conduct clinical research and development of their promising pipeline of product candidates in organ fibrosis and inflammatory diseases, including F351 (hydronidone) for liver fibrosis.

                            Brand Name : F351

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 30, 2023

                            Lead Product(s) : Hydronidone

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Beijing Continent Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth